JP2022512958A5 - - Google Patents
Info
- Publication number
- JP2022512958A5 JP2022512958A5 JP2021524959A JP2021524959A JP2022512958A5 JP 2022512958 A5 JP2022512958 A5 JP 2022512958A5 JP 2021524959 A JP2021524959 A JP 2021524959A JP 2021524959 A JP2021524959 A JP 2021524959A JP 2022512958 A5 JP2022512958 A5 JP 2022512958A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- nucleotide sequence
- hematopoietic
- cancer
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756683P | 2018-11-07 | 2018-11-07 | |
| US62/756,683 | 2018-11-07 | ||
| PCT/US2019/060287 WO2020097346A1 (en) | 2018-11-07 | 2019-11-07 | ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512958A JP2022512958A (ja) | 2022-02-07 |
| JP2022512958A5 true JP2022512958A5 (enExample) | 2022-11-11 |
Family
ID=70611157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524959A Pending JP2022512958A (ja) | 2018-11-07 | 2019-11-07 | トランス共刺激分子と組み合わされた抗ｇｐｃ３キメラ抗原受容体（ｃａｒ）及びその治療的用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220054545A1 (enExample) |
| EP (1) | EP3876950A4 (enExample) |
| JP (1) | JP2022512958A (enExample) |
| CN (1) | CN113260368B (enExample) |
| AU (1) | AU2019374828A1 (enExample) |
| CA (1) | CA3118889A1 (enExample) |
| WO (1) | WO2020097346A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN110468105B (zh) * | 2018-05-09 | 2024-03-22 | 恺兴生命科技(上海)有限公司 | 表达il-18r结合蛋白的免疫效应细胞 |
| WO2020037066A1 (en) | 2018-08-14 | 2020-02-20 | Unum Therapeutics Inc. | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| AU2020437669A1 (en) * | 2020-03-26 | 2022-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CD28H domain-containing chimeric antigen receptors and methods of use |
| CN113754778A (zh) * | 2020-06-05 | 2021-12-07 | 上海交通大学 | 靶向cldn18.2的嵌合抗原受体及其用途 |
| CN114057890A (zh) * | 2020-07-31 | 2022-02-18 | 南京北恒生物科技有限公司 | 新型共刺激结构域及其用途 |
| CN112159818B (zh) * | 2020-08-20 | 2023-02-21 | 山东兴瑞生物科技有限公司 | 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法 |
| US20240041924A1 (en) * | 2020-09-29 | 2024-02-08 | Nanjing Legend Biotech Co., Ltd. | T cell and antigen-presenting cell engagers and uses thereof |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US20240277841A2 (en) * | 2020-12-11 | 2024-08-22 | Purdue Research Foundation | Human chimeric antigen receptor neutrophils, compositions, kits and methods of use |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| EP4319794A4 (en) * | 2021-04-08 | 2025-03-12 | Artiva Biotherapeutics, Inc. | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING SAME |
| CA3217252A1 (en) * | 2021-04-19 | 2022-10-27 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and uses thereof in cellular therapies |
| CN117615786A (zh) * | 2021-05-07 | 2024-02-27 | 森蒂生物科学公司 | 嵌合抗原受体及其使用方法 |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| CA3237201A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| CN116426483B (zh) * | 2021-12-30 | 2024-02-23 | 南京紫珑生物科技有限公司 | Cd258蛋白在免疫治疗中的应用 |
| WO2024015995A2 (en) * | 2022-07-15 | 2024-01-18 | Albert Einstein College Of Medicine | Chimeric antigen receptors comprising a tmigd2 costimulatory domain and associated methods of using the same |
| CN117304343B (zh) * | 2023-10-11 | 2024-05-07 | 北京景达生物科技有限公司 | Gpc3靶向的car-nk细胞的制备及其应用 |
| CN117247466B (zh) * | 2023-11-20 | 2025-01-24 | 北京艺妙神州医药科技有限公司 | 抗磷脂酰肌醇蛋白聚糖3的嵌合抗原受体及其用途 |
| AU2024415858A1 (en) * | 2023-12-27 | 2026-07-16 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of il15 and light |
| WO2025191139A1 (en) * | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of her2-specific antigen binding proteins and cytokines |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| EP3097117B1 (en) * | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| ES2851123T1 (es) * | 2014-09-26 | 2021-09-03 | Baylor College Medicine | Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva |
| US11376326B2 (en) * | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
-
2019
- 2019-11-07 CA CA3118889A patent/CA3118889A1/en active Pending
- 2019-11-07 JP JP2021524959A patent/JP2022512958A/ja active Pending
- 2019-11-07 CN CN201980087101.8A patent/CN113260368B/zh not_active Expired - Fee Related
- 2019-11-07 WO PCT/US2019/060287 patent/WO2020097346A1/en not_active Ceased
- 2019-11-07 EP EP19882878.2A patent/EP3876950A4/en not_active Withdrawn
- 2019-11-07 US US17/291,963 patent/US20220054545A1/en not_active Abandoned
- 2019-11-07 AU AU2019374828A patent/AU2019374828A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230416339A1 (en) | Chimeric transmembrane proteins and uses thereof | |
| CN113260368B (zh) | 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途 | |
| AU2017226269B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| RU2747733C1 (ru) | Терапевтические средства | |
| JP6813491B2 (ja) | サイトカイン融合タンパク質 | |
| EP3724320B1 (en) | Cell | |
| KR102659440B1 (ko) | 키메라 폴리펩티드 및 그의 세포 막 내 국재화를 변경시키는 방법 | |
| US12570958B2 (en) | Single- and multi-chain chimeric antigen receptors | |
| JP7723420B2 (ja) | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 | |
| KR20230061486A (ko) | 면역 세포 내 어댑터의 유도성 발현을 위한 시스템 | |
| JP7755597B2 (ja) | 細胞 | |
| JP2022537066A (ja) | キメラタンパク質を発現するｔ細胞 | |
| Wan | Département de Médecine | |
| HK40102809A (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| HK40109852A (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| WO2025191154A1 (en) | Therapeutic agents | |
| HK40102436A (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| HK40102439A (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| CN117120598A (zh) | 激活和增殖暴露于抗原的cd8 t细胞的方法、由此制备的具有增强的抗癌活性的cd8 t细胞及其用途 | |
| HK40046928A (en) | Chimeric transmembrane proteins and uses thereof |